JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Bempedoic acid (ESP-55016; ETC-1002), a novel and potent ATP-citrate lyase (ACL) inhibitor, is an orally bioavailable, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. Bempedoic acid is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up statins. Bempedoic acid is a regulator of lipid and carbohydrate metabolism.
References:
1. PinkoskySL, et al. AMP-activated protein kinase and ATP-citrate lyase are twodistinct molecular targets for ETC-1002, a novel small moleculeregulator of lipid and carbohydrate metabolism. J Lipid Res. 2013Jan; 54(1):134-51.
2. FilippovS, et al. ETC-1002 regulates immune response, leukocyte homing, andadipose tissue inflammation via LKB1-dependent activation of macrophageAMPK. J Lipid Res. 2013 Aug; 54(8):2095-108.
3. Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia. J Clin Lipidol. 2015 May-Jun; 9(3):384-9.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!